MedTrace Logo

Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women

NCT05402852 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-06-02

No results posted yet for this study

Summary

EuBone is prepared by mixing eucommia ulmoides extract, fructus ulmoides extract and dodder extract in proportion. The aim of this study is to evaluate the effectiveness and safety of EuBone® capsules in slowing bone loss, preventing bone loss, and improving quality of life compared with placebo in Postmenopausal women.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

EuBone ® capsule

Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.

DRUG

placebo

Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.

Sponsors & Collaborators

  • Qianfoshan Hospital

    collaborator OTHER

  • Chenland Nutritionals lnc.

    collaborator UNKNOWN

  • Jinan Hetai Pharmaceutical Technology Co., LTD

    collaborator UNKNOWN

  • Shandong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-10-31
Completion
2023-12-31

Countries

  • China

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05402852 on ClinicalTrials.gov